CAR T-cell Therapy

The FDA has granted a priority review to axicabtagene ciloleucel for transplant-ineligible patients with relapsed or refractory non-Hodgkin lymphoma.

Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, discusses the status of chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).

Sophie Papa, PhD, MBBS, MRCP, medical oncologist, Clinical Academic Group, Department of Research Oncology, King’s College London, discusses leukapheresis manufacturing approach in head and neck cancer.

John P. Leonard, MD, discusses advancements across hematologic malignancies and pivotal trial data he is anticipating at the 2017 ASCO Annual Meeting.

The first cerebral edema death in the ZUMA-1 CAR T-cell therapy trial was disclosed today by Kite Pharma on a conference call with investors announcing the company’s first quarter financial results.

JUNO Therapeutics announced that it hopes to accelerate its process for developing CAR T cells from weeks to just 2 days.

Sattva S. Neelapu, MD, discusses the ZUMA-1 trial and the potential impact of these results on patients with non-Hodgkin lymphoma.

John P. Leonard, MD, associate dean of Clinical Research, interim chair of the Department of Medicine, Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the emergence and potential of chimeric antigen receptor (CAR) T-cell therapy across hematologic malignancies.

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in the field of multiple myeloma.

Sophie Papa, PhD, MBBS, MRCP, medical oncologist, Clinical Academic Group, Department of Research Oncology, King’s College London, discusses the impact of a recent study of chimeric antigen receptor (CAR) T cells in head and neck squamous cell carcinoma.

Low disease burden prior to treatment with CD19-specific chimeric antigen receptor T-cell therapy appears to be a positive prognostic factor for long-term survival outcomes of patients with relapsed B-cell acute lymphoblastic leukemia.

A novel target, B-cell maturation antigen, has been identified for future therapeutic development as chimeric antigen receptor T-cell therapy for patients with multiple myeloma.

Sophie Papa, MD, discusses the early-phase results and the logic behind studying CAR T-cell therapy in solid tumors, such as head and neck cancer.

Frederick L. Locke, MD, discusses the ZUMA-1 trial in non-Hodgkin lymphoma and the next steps going forward.

Sophie Papa, PhD, MBBS, MRCP, King’s College London in the United Kingdom, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with head and neck cancer.

Alfred L. Garfall, MD, discusses the latest developments with CAR T-cell therapy in hematologic malignancies

The flexibility of CAR T cells to perform multiple functions was associated with the level of clinical activity elicited for patients with advanced non-Hodgkin’s lymphoma, according to a retrospective analysis presented at the 2017 AACR Annual Meeting.

Results of a phase II trial showed that more than 80% of patients with refractory non-Hodgkin lymphoma achieved objective responses to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel.

Sophie Papa, PhD, MBBS, MRCP, King’s College London in the United Kingdom, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with head and neck cancer.

The FDA has granted a priority review designation to tisagenlecleucel-T as a treamtnet for pediatric and young adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia, making it the first CAR T-cell therapy to enter regulatory review.

Michel Sadelain, MD, PhD, discusses CRISPR and its effect on CAR T cells.

Stephan Grupp, MD, PhD, discusses the phase II ELIANA study results and the next steps with chimeric antigen receptor T-cell therapy in acute lymphoblastic leukemia.

Alfred L. Garfall, MD, MS, assistant professor of Medicine, the Hospital of the University of Pennsylvania, discusses the impact of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.

Leo I. Gordon MD, discusses results from the TRANSCEND trial and the next steps with chimeric antigen receptor T-cell therapy in non-Hodgkin lymphoma.

Ola Landgren, MD, PhD, discusses a new clinical trial at Memorial Sloan Kettering examining a novel myeloma-directed CAR T-cell therapy developed by researchers at the cancer center.

Juno therapeutics has shifted its focus toward the development of JCAR017 for relapsed/refractory diffuse large B-cell lymphoma after a series of toxicity-related setbacks culminated in the need to halt the development of JCAR015.

Chimeric antigen receptor T-cell therapies have already produced clinical trial results that, even by the lofty standards set by emerging immunotherapies, have been stunning.

Treatment with axicabtagene ciloleucel demonstrated an objective response rate of 82% and a complete response rate of 54% for patients with aggressive non-Hodgkin lymphoma.

Proper care coordination and patient education are essential to the success of delivering chimeric antigen receptor T-cell therapy, particularly in preparing patients for potential adverse events.

Fred Locke, MD, Moffitt Cancer Center discusses the interim results of the ZUMA-I trial of Kte-C19, a CAR T-cell therapy.